234 related articles for article (PubMed ID: 9573280)
1. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine.
Kemp SD; Shi C; Bloor S; Harrigan PR; Mellors JW; Larder BA
J Virol; 1998 Jun; 72(6):5093-8. PubMed ID: 9573280
[TBL] [Abstract][Full Text] [Related]
2. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572
[TBL] [Abstract][Full Text] [Related]
3. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
4. 3'-Azido-3'-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1.
Mansky LM; Bernard LC
J Virol; 2000 Oct; 74(20):9532-9. PubMed ID: 11000223
[TBL] [Abstract][Full Text] [Related]
5. A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine.
Smith RA; Remington KM; Preston BD; Schinazi RF; North TW
J Virol; 1998 Mar; 72(3):2335-40. PubMed ID: 9499094
[TBL] [Abstract][Full Text] [Related]
6. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis.
Götte M; Arion D; Parniak MA; Wainberg MA
J Virol; 2000 Apr; 74(8):3579-85. PubMed ID: 10729133
[TBL] [Abstract][Full Text] [Related]
7. Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies.
Mansky LM; Pearl DK; Gajary LC
J Virol; 2002 Sep; 76(18):9253-9. PubMed ID: 12186909
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
9. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC.
Krebs R; Immendörfer U; Thrall SH; Wöhrl BM; Goody RS
Biochemistry; 1997 Aug; 36(33):10292-300. PubMed ID: 9254628
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine.
Zelina S; Sheen CW; Radzio J; Mellors JW; Sluis-Cremer N
Antimicrob Agents Chemother; 2008 Jan; 52(1):157-63. PubMed ID: 17967907
[TBL] [Abstract][Full Text] [Related]
11. Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC.
Girouard M; Diallo K; Marchand B; McCormick S; Götte M
J Biol Chem; 2003 Sep; 278(36):34403-10. PubMed ID: 12819190
[TBL] [Abstract][Full Text] [Related]
12. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
Bazmi HZ; Hammond JL; Cavalcanti SC; Chu CK; Schinazi RF; Mellors JW
Antimicrob Agents Chemother; 2000 Jul; 44(7):1783-8. PubMed ID: 10858331
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
[TBL] [Abstract][Full Text] [Related]
14. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
Larder BA; Kemp SD; Harrigan PR
Science; 1995 Aug; 269(5224):696-9. PubMed ID: 7542804
[TBL] [Abstract][Full Text] [Related]
15. Toxicology and Carcinogenesis Studies of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in utero and postnatal gavage studies).
National Toxicology Program
Natl Toxicol Program Genet Modif Model Rep; 2013 Oct; (16):1-236. PubMed ID: 24503698
[TBL] [Abstract][Full Text] [Related]
16. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.
Nijhuis M; Schuurman R; de Jong D; van Leeuwen R; Lange J; Danner S; Keulen W; de Groot T; Boucher CA
J Infect Dis; 1997 Aug; 176(2):398-405. PubMed ID: 9237704
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.
von Wyl V; Ehteshami M; Symons J; Bürgisser P; Nijhuis M; Demeter LM; Yerly S; Böni J; Klimkait T; Schuurman R; Ledergerber B; Götte M; Günthard HF;
J Infect Dis; 2010 Apr; 201(7):1054-62. PubMed ID: 20170373
[TBL] [Abstract][Full Text] [Related]
18. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.
Lukashov VV; Huismans R; Jebbink MF; Danner SA; de Boer RJ; Goudsmit J
AIDS Res Hum Retroviruses; 2001 Jun; 17(9):807-18. PubMed ID: 11429122
[TBL] [Abstract][Full Text] [Related]
19. Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals.
Brindeiro R; Vanderborght B; Caride E; Correa L; Oravec RM; Berro O; Stuyver L; Tanuri A
Antimicrob Agents Chemother; 1999 Jul; 43(7):1674-80. PubMed ID: 10390221
[TBL] [Abstract][Full Text] [Related]
20. A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.
Smith RA; Klarmann GJ; Stray KM; von Schwedler UK; Schinazi RF; Preston BD; North TW
Antimicrob Agents Chemother; 1999 Aug; 43(8):2077-80. PubMed ID: 10428942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]